Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome

Table 2 Plasma levels of sTREM-1 by clinical manifestations of PAPS (n = 33) compared with controls (n = 73)

Clinical manifestation of PAPS (n)	Mean ± SD (pg/ml)	Median (pg/ml)	Range (pg/ml)	P value*
Past thrombosis (19)	289.5 ± 94.65	287.5	138.04–532.7	NS
Current thrombosis (7)	429.6 ± 227.5	303.3	203.3–817.6	< 0.0001
Past obstetric event (7)	195.1 ± 58.5	198.3	90.4–284.2	NS
Current arterial thrombosis (5)	377.2 ± 180.41	283.3	203.3–601.4	0.001
Venous thromboembolism-ever (9)	366.67 ± 203.79	316.82	141.98-817.62	0.012
MI-ever (5)	371.6 ± 250.04	257.7	238.42–817.62	0.003
Stroke-ever (14)	307.2 ± 105.6	287.9	170.02–540.29	0.03

MI myocardial infarction, NS not statistically significant, PAPS primary antiphospholipid syndrome, sTREM-1 soluble receptor expressed on myeloid cells-1
*Analysis of differences in mean plasma sTREM-1 level between patients with various clinical manifestations of PAPS and healthy controls; mean sTREM-1 of the healthy control group, 230.18 ± 85.52 pg/ml

ISSN: 1478-6362